By John Carroll Genentech has anted up $12 million to expand its development pact for Seattle Genetics’ antibody-drug conjugate (ADC) technology. And the Seattle biotech will now be able to play for a pot of cash that could swell to $900 million in fees and milestones. Genentech has already shelled out $30 million to Seattle …
By John Carroll London-based MRC Technology has inked a licensing pact with Genentech for a package of small molecule drug candidates for neurological conditions. MRC gets an unspecified upfront payment along with a slate of potential milestones for the licensing deal, the first major small molecule collaboration MRC has struck for its Centre for Therapeutics Discovery. …
By John Carroll AstraZeneca’s new licensing chief, Shaun Grady, traveled to Chicago to spread the word about the pharma company’s new partnering strategy at BIO. AstraZeneca has been reengineering its approach to drug development recently, moving away from an in-house approach to a new strategy that will look for external deals to drive 40 percent …
By Maureen Martino Evotec has signed a multi-year integrated drug discovery alliance with Roche’s Genentech to discover novel small molecule therapeutics. Evotec will use its integrated and innovative drug discovery platform against targets nominated by Genentech to identify development candidates. Financial details of the deal were not disclosed. “We are proud that Genentech, one of the …
